Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1967
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1973 1
1981 1
1986 1
1987 1
1988 2
1989 2
1991 1
1992 1
1994 2
1995 2
1996 2
1997 2
1998 1
2000 3
2001 3
2002 2
2003 2
2004 3
2005 3
2007 2
2008 1
2009 1
2010 1
2011 4
2012 1
2014 3
2015 6
2016 5
2017 3
2018 6
2019 4
2020 4
2021 7
2022 5
2023 6
2024 9
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.
Andrade J, Khairy P, Dobrev D, Nattel S. Andrade J, et al. Circ Res. 2014 Apr 25;114(9):1453-68. doi: 10.1161/CIRCRESAHA.114.303211. Circ Res. 2014. PMID: 24763464 Review.
Atrial fibrillation (AF) is the most common arrhythmia (estimated lifetime risk, 22%-26%). The aim of this article is to review the clinical epidemiological features of AF and to relate them to underlying mechanisms. ...Emerging risk factors include prehypertension, increa …
Atrial fibrillation (AF) is the most common arrhythmia (estimated lifetime risk, 22%-26%). The aim of this article is to review the c …
Artificial Intelligence Interpretation of the Electrocardiogram: A State-of-the-Art Review.
Ose B, Sattar Z, Gupta A, Toquica C, Harvey C, Noheria A. Ose B, et al. Curr Cardiol Rep. 2024 Jun;26(6):561-580. doi: 10.1007/s11886-024-02062-1. Epub 2024 May 16. Curr Cardiol Rep. 2024. PMID: 38753291 Review.
Subsequently, AI-ECG models have been developed for screening structural heart disease including hypertrophic cardiomyopathy, cardiac amyloidosis, aortic stenosis, pulmonary hypertension, and left ventricular systolic dysfunction. ...
Subsequently, AI-ECG models have been developed for screening structural heart disease including hypertrophic cardiomyopathy, …
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, Bronis K, Papageorgiou N, Chow A, Rowland E, Lowe M, Segal OR, Lambiase PD. Providencia R, et al. Heart. 2016 Oct 1;102(19):1533-43. doi: 10.1136/heartjnl-2016-309406. Epub 2016 May 27. Heart. 2016. PMID: 27234160 Review.
OBJECTIVE: Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and is associated with a high risk of stroke. The efficacy and safety of catheter ablation in this setting is poorly characterised. ...Freedom from AF/atrial tachycardia relapse was h …
OBJECTIVE: Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and is associated with a high risk of strok …
Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.
Ye TTS, Siah QZ, Tan BYQ, Ho JSY, Syn NLX, Teo YH, Teo YN, Yip JW, Yeo TC, Lin W, Wong RCC, Chai P, Chan B, Sharma VK, Yeo LLL, Sia CH. Ye TTS, et al. J Thromb Thrombolysis. 2023 Jan;55(1):83-91. doi: 10.1007/s11239-022-02713-6. Epub 2022 Oct 3. J Thromb Thrombolysis. 2023. PMID: 36192663 Review.
Hypertrophic cardiomyopathy predisposes to acute cerebrovascular events including ischaemic stroke, transient ischaemic attack and systemic thromboembolism. ...The apical subgroup shows a similar risk of acute cerebrovascular events as the overall hypertrophic
Hypertrophic cardiomyopathy predisposes to acute cerebrovascular events including ischaemic stroke, transient ischaemic attack
Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies.
Mazur M, Braksator W, Popjes E. Mazur M, et al. Curr Cardiol Rep. 2024 Sep;26(9):985-994. doi: 10.1007/s11886-024-02095-6. Epub 2024 Jul 11. Curr Cardiol Rep. 2024. PMID: 38990491 Review.
PURPOSE OF REVIEW: There has been much debate surrounding novel medical therapies and heart transplantation listing challenges in patients with hypertrophic cardiomyopathy (HCM). RECENT FINDINGS: Recent clinical trials led to FDA approval of mavacamten (a cardiac my …
PURPOSE OF REVIEW: There has been much debate surrounding novel medical therapies and heart transplantation listing challenges in patients w …
Transcatheter Myotomy for Hypertrophic Obstructive Cardiomyopathy.
Danek B, Elison D, Chung CJ, McCabe JM. Danek B, et al. Curr Cardiol Rep. 2024 Dec;26(12):1471-1476. doi: 10.1007/s11886-024-02145-z. Epub 2024 Oct 19. Curr Cardiol Rep. 2024. PMID: 39425812 Review.
PURPOSE OF REVIEW: To describe the emerging role of transcatheter septal myotomy in the treatment of hypertrophic obstructive cardiomyopathy. RECENT FINDINGS: Transcatheter septal myotomy was developed to address risk of LVOT obstruction during TMVR, however it has …
PURPOSE OF REVIEW: To describe the emerging role of transcatheter septal myotomy in the treatment of hypertrophic obstructive card
Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations.
Saul T, Bui QM, Argiro A, Keyt L, Olivotto I, Adler E. Saul T, et al. ESC Heart Fail. 2024 Dec;11(6):3501-3510. doi: 10.1002/ehf2.14848. Epub 2024 May 21. ESC Heart Fail. 2024. PMID: 38773858 Free PMC article. Review.
Hypertrophic cardiomyopathy (HCM) due to thick filament variants is more common; however, HCM due to thin filament variants (HCM-Thin) may be associated with a more malignant phenotype with an increased risk of sudden cardiac death. ...In regard to left ventricular
Hypertrophic cardiomyopathy (HCM) due to thick filament variants is more common; however, HCM due to thin filament variants (H
Myocardial bridging.
Alegria JR, Herrmann J, Holmes DR Jr, Lerman A, Rihal CS. Alegria JR, et al. Eur Heart J. 2005 Jun;26(12):1159-68. doi: 10.1093/eurheartj/ehi203. Epub 2005 Mar 11. Eur Heart J. 2005. PMID: 15764618 Review.
Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Vaidya K, Semsarian C, Chan KH. Vaidya K, et al. Heart Lung Circ. 2017 Sep;26(9):975-982. doi: 10.1016/j.hlc.2017.05.116. Epub 2017 May 23. Heart Lung Circ. 2017. PMID: 28602671 Review.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder with a spectrum of clinical manifestations. ...
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder with a spectrum of clinical manifestations. ...
Novel Pharmacotherapy in Hypertrophic Cardiomyopathy.
Andries G, Yandrapalli S, Naidu SS, Panza JA. Andries G, et al. Cardiol Rev. 2018 Sep/Oct;26(5):239-244. doi: 10.1097/CRD.0000000000000211. Cardiol Rev. 2018. PMID: 29746257 Review.
Hypertrophic cardiomyopathy (HCM) is an inherited disease characterized by unexplained left ventricular hypertrophy. ...
Hypertrophic cardiomyopathy (HCM) is an inherited disease characterized by unexplained left ventricular hypertrophy. ...
93 results